First Tracks Biotherapeutics Reports Positive Phase 1b ANB033 Results
The company said ANB033 showed statistically significant protection against gluten-induced intestinal damage and symptoms.
Key Highlights:Original SEC Filing: First Tracks Biotherapeutics, Inc. [ TRAX ] - 8-K - Oct. 13, 2026This is an AI-p…